European Journal of Cancer Care最新文献

{"title":"Adopting a Dyadic Approach to Treating Chronic Cancer-Related Fatigue: A Mixed Methods Study to Assess Patients’ and Partners’ Needs, Benefits, Barriers and Preferences","authors":"Sophie I. van Dongen,&nbsp;Fabiola Müller,&nbsp;Rosalie A. M. van Woezik,&nbsp;Mariët Hagedoorn,&nbsp;Marije L. van der Lee","doi":"10.1155/ecc/8313220","DOIUrl":"https://doi.org/10.1155/ecc/8313220","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Chronic cancer-related fatigue (CCRF) is a common symptom among patients. Current therapies target the patient alone, while evidence suggests that targeting the dyad might be more beneficial.</p>\u0000 <p><b>Method:</b> Using a mixed methods design, we conducted two studies that together aimed to provide more insight into the needs, benefits, barriers and preferences regarding a couples therapy for CCRF. In a qualitative study, we conducted focus groups and semi-structured interviews with a purposive sample of 10 patients and 10 partners with experience of CCRF care, followed by thematic analysis. In a subsequent quantitative study, a convenience sample of patients (<i>n</i> = 172) and partners (<i>n</i> = 55) completed an online survey developed based on the qualitative findings.</p>\u0000 <p><b>Results:</b> In the qualitative study, both patients and partners expressed that a couples therapy could help them. Perceived benefits included empowerment of partners to support patients and improved couples communication. In the online survey, the need for a dyadic approach to CCRF therapy was confirmed by both patients (39%) and partners (91%). The benefits reported by most patients and partners were that partners could get attention for their own problems related to the patients’ cancer and fatigue (patients: 72%, partners: 86%) and receive advice on coping with fatigue (66% and 90%, respectively). Participants in both studies identified barriers, such as a fear of burdening partners with a couples therapy (50%). Partner involvement was considered desirable for most therapy elements (e.g., psychoeducation, contact with the therapist, exercises and relapse prevention). Yet, individual preferences varied widely.</p>\u0000 <p><b>Conclusion:</b> Results of both studies support the potential acceptability of a couples therapy for CCRF among patients and partners. Based on divergent preferences, we determined that a couples therapy must provide flexibility regarding the degree, intensity and type of partner involvement. Dyadic psychoeducation can be used as a solid starting point to manage expectations and get relief from perceived barriers.</p>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/8313220","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143115422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Awareness and Knowledge of Chemotherapy Among Cancer Patients at Suresh Wagle Memorial Cancer Centre, Kathmandu","authors":"Sabina Tamang,&nbsp;Urmila Prajapati,&nbsp;Gayatri Maharjan","doi":"10.1155/ecc/6384002","DOIUrl":"https://doi.org/10.1155/ecc/6384002","url":null,"abstract":"<div>\u0000 <p>Chemotherapy plays a crucial role in cancer treatment, targeting rapidly dividing abnormal and normal cells, which often leads to significant side effects. This study aimed to assess the awareness of chemotherapy among cancer patients at Suresh Wagle Memorial Cancer Centre, Tribhuvan University Teaching Hospital (TUTH), Kathmandu, Nepal. A descriptive cross-sectional design was employed, involving 103 cancer patients selected through nonprobability, purposive sampling. Data were collected via in-person interviews using a semistructured questionnaire. Statistical analysis, including chi-square tests, was conducted to explore associations between patients’ knowledge of chemotherapy and biodemographic variables. The results indicated that nearly half of the respondents, 50 (48.5%), had moderate knowledge of chemotherapy, while a significant association was found between the cycle of chemotherapy and access to health information, with a <i>p</i> value of less than 0.05. The study highlights the need for regular patient education and counseling to enhance awareness and understanding of chemotherapy. The use of educational materials such as brochures, videos, and online resources is recommended to reinforce patients’ knowledge and improve their overall quality of life during treatment.</p>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/6384002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143115077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Sexual Well-Being Support for Men With Prostate Cancer: The Health Professional Perspective","authors":"Megan Charlick,&nbsp;Kerry Ettridge,&nbsp;Tenaw Tiruye,&nbsp;Michael O’Callaghan,&nbsp;Sally Sara,&nbsp;Alexander Jay,&nbsp;Kerri Beckmann","doi":"10.1155/ecc/2875201","DOIUrl":"https://doi.org/10.1155/ecc/2875201","url":null,"abstract":"<div>\u0000 <p><b>Purpose:</b> The provision of evidenced-based sexual well-being support is considered a key metric of quality prostate cancer care. However, patients continually report high rates of unmet sexual health needs. To provide insight into the challenges healthcare professionals (HCPs) face in delivering sexual well-being support, we conducted a qualitative study.</p>\u0000 <p><b>Methods:</b> HCPs were recruited via professional organisations/networks and snowballing. Interviews were semistructured, conducted via telephone/video and transcribed verbatim. Interviews explored work experience, sexual support provided, challenges faced and areas of prioritisation to improve care delivery. Data were analysed using reflexive thematic analysis. The lack of representation from urologists and radiation oncologists was a limitation.</p>\u0000 <p><b>Results:</b> Twenty-one HCPs were interviewed, including nurses, pharmacists, sexologists, a physiotherapist and an oncologist. Eight key themes were identified. Themes 1–5 describe the challenges faced by HCPs in providing sexual well-being support, such as logistical issues and reliance on other HCPs. The remaining three themes describe areas of change recommended by HCPs to improve delivery of support, including standardisation of penile rehabilitation guidelines, training for specialists and GPs and prioritisation of multidisciplinary sexual well-being support as part of routine care.</p>\u0000 <p><b>Conclusions:</b> HCPs face several challenges in providing sexual well-being support to prostate cancer patients, which could be ameliorated through greater awareness and education about the importance of sexual well-being support and through standardising pathways and guidelines. Addressing challenges faced by HCPs in the delivery of sexual well-being support may ultimately improve patient experiences and reduce unmet sexual health needs following prostate cancer treatment.</p>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/2875201","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143114141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Nobiletin and 5-Demethylnobiletin as Cancer Chemopreventive Agents","authors":"Marisol Rosas-Martínez,&nbsp;Gloria Gutiérrez-Venegas","doi":"10.1155/ecc/1128095","DOIUrl":"https://doi.org/10.1155/ecc/1128095","url":null,"abstract":"<div>\u0000 <p>Natural chemicals have been considered as promising molecules in cancer treatment because of their broad spectrum of activities. Flavonoids show high affinity against key molecular targets associated with developing cancer, and tumor cells exhibit an inability to resist flavonoid treatment. Flavonoids are natural molecules synthesized during secondary plant metabolism that has protective activities against biotic and abiotic factors (animals, bacteria, and fungi) and are resistant to ultraviolet light, temperature, and solid minerals and contaminants. They have been purified from plants and synthetic molecules and have an antioxidant, antitumor, and cardioprotective activities in humans. The large flavonoid family includes polymethoxyflavones, which are extracted from the peels of citrus fruits such as <i>Citrus nobilis</i>, from which nobiletin (NOB) is obtained. The compounds derived from this promising anticancer chemical include 5-demethylnobiletin (5-DMN). These compounds inhibit a large number of targets that regulate the hallmarks of cancer by inducing apoptosis, cell cycle arrest, inhibition of proliferation, epithelial–mesenchymal transition, limiting migration, and angiogenesis. 5-DMN has exhibited potency in the regulation of anticancer activities. This review was conducted to summarize and compare the effects of NOB and 5-DMN on different types of cancer.</p>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2024 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/1128095","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142861075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship Between Upper-Limb Lymphedema and Fatigue Among Breast Cancer Survivors","authors":"Masood Soltanipur,&nbsp;Hossein Yarmohammadi,&nbsp;Sina Shahshenas,&nbsp;Fereshteh Abbasvandi,&nbsp;Ali Montazeri,&nbsp;Zahra Sheikhi","doi":"10.1155/ecc/3452139","DOIUrl":"https://doi.org/10.1155/ecc/3452139","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Breast cancer survivors (BCSs) often face long-term complications, with upper-limb lymphedema and cancer-related fatigue (CRF) being challenging. This study aimed to investigate the relationship between upper-limb lymphedema and fatigue among BCSs.</p>\u0000 <p><b>Method:</b> This cross-sectional study was performed on 102 BCSs, of which 31 (30.4%) had breast cancer–related lymphedema. Duration, stage, and excess volume were considered as indicators of breast cancer–related lymphedema severity. QoL was measured using the EORTC QLQ-C30. The score of the fatigue symptom scale was used based on EORTC QLQ-C30 for CRF assessment. Also, the brief fatigue inventory was used to measure the severity of fatigue among participants.</p>\u0000 <p><b>Results:</b> The mean fatigue symptom scale and brief fatigue inventory scores were 37.90 ± 24.59 and 3.69 ± 1.25, respectively. The mean fatigue symptom scale was significantly different among BCSs with BMI ≤ 25 and BMI &gt; 25 (29.59 ± 24.49 vs. 41.51 ± 23.88, <i>p</i> = 0.026). Also, the mean brief fatigue inventory was significantly different among BCSs with the number of dissected lymph nodes (LNs) ≤ 5 and &gt; 5 (3.52 ± 1.18 vs. 4.08 ± 1.34, <i>p</i> = 0.042). Additionally, women with breast cancer–related lymphedema had significantly higher scores of fatigue symptom scale and brief fatigue inventory (46.59 ± 27.12 vs. 34.11 ± 22.56, <i>p</i> = 0.03, and 4.75 ± 1.21 vs. 3.22 ± 0.96, <i>p</i> = 0.001, respectively). Except for a weak correlation between BMI and fatigue symptom scale and brief fatigue inventory (<i>r</i>: 0.279, <i>p</i> = 0.004, and <i>r</i>: 0.313, <i>p</i> = 0.001, respectively), there was no other significant relationship between CRF and study variables such as breast cancer–related lymphedema duration, stage, and excess volume. Meanwhile, fatigue symptom scale and brief fatigue inventory were significantly correlated with global health and functional scale scores of EORTC QLQ-C30. The ROC curve which models the diagnostic efficacy for fatigue symptom scale showed an AUC of 0.634 (<i>p</i> = 0.034, 95% CI: 0.510–0.759), while the ROC curve which models the diagnostic efficacy for brief fatigue inventory showed an AUC of 0.821 (<i>p</i> &lt; 0.001, 95% CI: 0.735–0.908).</p>\u0000 <p><b>Conclusion:</b> This study highlighted that while breast cancer–related lymphedema was associated with increased CRF, the severity of lymphedema did not significantly correlate with CRF. Additionally, CRF might be an indicator of breast cancer–related lymphedema among BCSs.</p>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2024 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/3452139","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142861295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development Process of a Holistic Assessment Questionnaire to Measure and Monitor Cancer-Related Fatigue","authors":"Kim A. E. Wijlens,&nbsp;Annemieke Witteveen,&nbsp;Lian Beenhakker,&nbsp;Sabine Siesling,&nbsp;Miriam M. R. Vollenbroek-Hutten,&nbsp;Christina Bode","doi":"10.1155/2024/2671255","DOIUrl":"https://doi.org/10.1155/2024/2671255","url":null,"abstract":"<div>\u0000 <p><b>Purpose:</b> To understand the consequences of diseases and treatment such as cancer and thus the needs of patients for surveillance and care and to improve quality of life, patients should be assessed using a holistic approach. However, instruments to create such a holistic view do not exist and the development presents unique challenges. Therefore, this study presents a method for the development of a holistic assessment questionnaire using cancer-related fatigue (CRF) as a case.</p>\u0000 <p><b>Method:</b> We started with (1) the definition of our construct of interest (CRF) on the theme level followed by (2) item selection, an iterative process of searching for validated questionnaires that together cover the full holistic construct. The construct definition on theme level (1) was too broad and was, therefore, redefined on the element level (construct &gt; theme &gt; element) based on interviews with relevant stakeholders. Hereafter, item selection (2) was performed on the element level based on a priority list, psychometric properties (e.g., discriminative parameter value) and consultation of experts and future users. Lastly, (3) items were reformulated.</p>\u0000 <p><b>Results:</b> Initial CRF construct definition (1) resulted in 110 relevant validated questionnaires with over three thousand items, requiring a construct redefinition on element level. Seventy-two items from 21 validated questionnaires were included (2) in the preliminary holistic assessment questionnaire. For item reformulation (3), easy language was used to better suit the target population.</p>\u0000 <p><b>Conclusion:</b> Tailoring care to the individual requires a holistic view. This article presents a novel method to develop a holistic assessment questionnaire, including an example for CRF, with several recommendations for cancer-specific instrument development. Although the development process of a holistic assessment questionnaire is time-consuming, more late and long-term effects of cancer are multidimensional and could benefit from a holistic approach in their assessment to enable personalised care, thereby improving quality of life and reducing societal impact.</p>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2024 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/2671255","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Faecal Immunochemical Testing in Symptomatic Primary Care Patients: A Diagnostic Accuracy Study","authors":"Alex J. Ball,&nbsp;Meghna Ray,&nbsp;Arif Manji,&nbsp;Imran Aziz,&nbsp;Ravishankar B. Sargur,&nbsp;Matthew Kurien","doi":"10.1155/2024/4849620","DOIUrl":"https://doi.org/10.1155/2024/4849620","url":null,"abstract":"<div>\u0000 <p><b>Aim:</b> The faecal immunochemical test (FIT) is now widely used in English primary care to triage people who exhibit signs or symptoms of colorectal cancer (CRC). National guidelines for FIT implementation were based on data that acknowledged limitations. This study examines FIT accuracy in primary care patients with low- and high-risk symptoms of CRC.</p>\u0000 <p><b>Methods:</b> This study describes a retrospective cohort study in South Yorkshire, UK (<i>n</i> = 2029). Consecutive symptomatic adult patients in primary care undergoing a FIT between 01/04/2021 and 30/04/2021 were assessed. A threshold &gt; 10 μg Hb/g was defined as a positive FIT result. Lower gastrointestinal tract (LGI) investigations were the reference standard. Follow-up over 24 months was used to identify serious colorectal diseases (CRC, high-risk polyps and inflammatory bowel disease [IBD]).</p>\u0000 <p><b>Results:</b> Five hundred and fifteen (25.4%) patients had a positive FIT. The CRC prevalence was 1.2% (24/2029). Nineteen (79.1%) of the 24 CRC cases had NG12 symptoms, with two (8.3%) having a negative FIT. For CRC detection, FIT showed 91.7% sensitivity (95% CI: 71.5%–98.5%), 75.4% specificity (95% CI: 73.4%–77.2%), 4.3% positive predictive value (PPV) (95% CI: 2.8%–6.5%) and 99.9% negative predictive value (NPV) (95% CI: 99.5%–99.97%). Combining CRC, high-risk polyps and IBD increased PPV and specificity but decreased sensitivity and NPV.</p>\u0000 <p><b>Conclusions:</b> In primary care, FIT safely triages patients having at-risk CRC risk symptoms. Negative FIT results indicate a low likelihood of CRC and supports safety-netting interventions.</p>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2024 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4849620","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142641391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferroptosis-Related LncRNA BCRP3 Promotes the Proliferation and Migration of Prostate Cancer","authors":"Peng Zhou,&nbsp;Yueying Gu,&nbsp;Wenchao Zhao,&nbsp;Hui Wang,&nbsp;Junhua Gu,&nbsp;Zhen Xu,&nbsp;Xin Jin","doi":"10.1155/2024/3569968","DOIUrl":"https://doi.org/10.1155/2024/3569968","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Long noncoding RNAs (lncRNAs) are reported that play an important role in regulating tumorigenesis. This study aims to develop a ferroptosis-related lncRNA gene signature for predicting biochemical recurrence of prostate cancer (PCa) and prove a functional lncRNA BCRP3 as a promotor toward PCa progression.</p>\u0000 <p><b>Methods:</b> The ferroptosis-related lncRNA were identified by interoperating the databases of The Cancer Genome Atlas (TCGA) and FerrDb. A predictive model for biochemical recurrence of PCa was established based on the LASSO Cox regression. Kaplan–Meier cures were applied in the measurement of the impact on patients’ survival caused by key lncRNAs. Meanwhile, the molecular assays of CCK8, EdU, wound healing, and Transwell were conducted to evaluate the tumor-suppressive effect of BCRP3 in vitro<i>.</i></p>\u0000 <p><b>Results:</b> This study presented that 17 differentially expressed ferroptosis-related lncRNAs were confirmed and further screened out 9 key lncRNAs for the establishment of risk model. The nomogram involved the risk model was also proved with an excellent predictive performance toward 1-, 3-, and 5-year survival with the area of curves (AUC) as 0.77, 0.79, and 0.65 separately. Notably, the lncRNA BCRP3 was significantly correlated with the survival of PCa patients based on multivariate Cox regression. Additionally, downregulation of BCRP3 effectively inhibited the proliferation, migration, and invasion of PC3 cells which further proved its anti-tumor function.</p>\u0000 <p><b>Conclusion:</b> We developed a ferroptosis-related lncRNA risk model for predicting biochemical recurrence, which assisting in the clinical therapy of patients with PCa.</p>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2024 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/3569968","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142574052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Correlation Between Serum Tumor Markers and Liver Metastasis of Lung Cancer","authors":"Xiaoyuan Bu,&nbsp;Xintong Shi,&nbsp;Yingjun Wu,&nbsp;Yinxiang Wu,&nbsp;Lu Li,&nbsp;Liping Gao,&nbsp;Zhiwei Xiao,&nbsp;Jiquan Chen","doi":"10.1155/2024/5195652","DOIUrl":"https://doi.org/10.1155/2024/5195652","url":null,"abstract":"<div>\u0000 <p><b>Purpose:</b> To investigate the relationship between the changes of lactate dehydrogenase (LDH), neuron-specific enolase (NSE), keratin-19 fragment antigen 21-1 (cyfra21-1), and liver metastases of lung cancer.</p>\u0000 <p><b>Methods:</b> Eighty patients who had lung cancer that had spread to their liver diagnosed in our hospital from October 2021 to October 2023 (Group A), 80 individuals with advanced lung cancer who have metastasized to other sites (Group B), and 80 individuals with lung cancer who have not spread (control group) were selected as the study objects. LDH, NSE, and serum cyfra21-1 levels of patients in the three groups were detected, and pathological results were used as the diagnostic gold standard. ROC curves were drawn to examine the clinical value of NSE, cyfra21-1, and LDH levels in the distinct types of lung cancer identification of liver metastases.</p>\u0000 <p><b>Results:</b> There was no remarkable variation in pathological types among the three groups (<i>p</i> &gt; 0.05), but there were remarkable variations in TNM stage and lymph node metastasis among the three groups (<i>p</i> &lt; 0.05). The levels of cyfra21-1, NSE, and LDH in Group A and Group B were greater compared to those in the control group (<i>p</i> &lt; 0.05), and the levels of cyfra21-1, NSE, and LDH in Group A were greater compared to those in Group B (<i>p</i> &lt; 0.05). The critical value, sensitivity, specificity, and area under the curve (AUC) of serum cyfra21-1 in the distinct identification of liver metastasis of lung cancer were 8.22 ng/mL, 37.42%, 65.18%, and 0.508, respectively. The critical value, sensitivity, specificity, and AUC of NSE for distinct types of lung cancer identification of liver metastases were 23.96 ng/mL, 64.56%, 81.23%, and 0.723, respectively. The critical value, sensitivity, specificity, and AUC of LDH for differential diagnosis of liver metastasis of lung cancer were 304.78 U/L, 75.65%, 85.73%, and 0.821.</p>\u0000 <p><b>Conclusion:</b> The serum levels of NSE, cyfra21-1, and LDH in patients with liver metastasis of lung cancer were remarkably greater compared to patients without liver metastasis, which can be useful as a clinical auxiliary in determining lung cancer metastasis.</p>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2024 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5195652","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142540980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influencing Factors and a Predictive Nomogram of Frailty in Chinese Patients with Cancer: A Single-Center Retrospective Study","authors":"Zhihui Yang,&nbsp;Yuanyuan Luo,&nbsp;Jiahui Luo,&nbsp;Qinghong Fang,&nbsp;Jingxia Miao,&nbsp;Lili Zhang","doi":"10.1155/2024/3194941","DOIUrl":"https://doi.org/10.1155/2024/3194941","url":null,"abstract":"<div>\u0000 <p><i>Objective</i>. The number of cancer survivors is increasing, and the high prevalence of frailty not only reduces quality of life but also affects the treatment of cancer patients. This study aimed to identify the prevalence and risk factors of frailty in cancer patients and to construct a nomogram to predict the probability of frailty. <i>Methods</i>. Nine hundred fifty-eight cancer patients were included in this retrospective study, randomly divided into a development set (<i>n</i> = 680) and a validation set (<i>n</i> = 278). Frailty was assessed using the Tilburg frailty indicator (TFI). Social support, medical coping styles, and psychological distress were assessed by the Social Support Self-Rating Scale (SSRS), Medical Coping Modes Questionnaire (MCMQ), and distress thermometer (DT), respectively. <i>Results</i>. The prevalence of frailty in cancer patients was 45.93%. Cancer patients who exercised regularly, ate a balanced diet, and actively coped with diseases were less likely to become frail. The risk factors for frailty identified by a multivariate analysis were parenteral nutrition, advanced TNM staging, vegetarian diet, unemployment, psychological distress ≥4, low physical activity, and negative coping styles. These risk factors were used to construct a nomogram, and the C-index, calibration curve, and decision curve analysis (DCA) were used to assess the performance of the nomogram. The C-index was 0.762, and the calibration curve showed satisfactory coherence. The net benefit of the nomogram was better between threshold probabilities of 17%–96% in DCA. <i>Conclusion</i>. Special focus needs to be placed on frail cancer patients due to their high prevalence and severe outcomes. Clinical medical workers could use this nomogram to identify high-risk patients and intervene early to prevent frailty.</p>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2024 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/3194941","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142313256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}